Company*
(Country; Symbol)

University/
Nonprofit@

Type Of Agreement

Product Area

Details (Date)


Adherex
Technologies
Inc.
(AMEX:ADH)

National Cancer Institute

Clinical trial agreement

The NCI is sponsoring studies of Adherex's ADH-1 (Exherin)

The agent targets N-cadherin, a protein present on certain tumor cells (4/5)

AEterna
Zentaris Inc.
Canada; AEZS

University
of Montreal

Agreement

Deal for preclinical research on the role of ghrelin in the development of obesity

The three-year project has an initial budget of C$1.2M (US$1M) (5/3)

Affymetrix
Inc.
(AFFX)

Korea's National Institute of Health

Agreement

The Korean NIH will use Affymetrix GeneChip technology in genomic studies

The institute and its collaborators are working in the areas of diabetes, hypertension, asthma and metabolic syndrome (3/8)

Alnylam
Pharmaceuticals
Inc.
(ALNY)

CBR Institute for Biomedical Research

License agreement

Alnylam got rights to technology that allows for targeted delivery of RNAi agents

The CBR Institute is an affiliate of Harvard Medical School; terms of the deal were not disclosed (5/9)

Alnylam
Pharmaceuticals
Inc.
(ALNY)

U.S. Army Medical Research Institute of Infectious Diseases

CRADA

Deal to discover RNAi therapeutics targeting viral organisms, fever viruses including hemorrhagic

Terms of the agreement were not disclosed (4/12)

Alnylam
Pharmaceuticals
Inc.
(ALNY)

Massachusetts Institute of Technology

Agreement

Alnylam got access to liposome technology

Alnylam has an option to license the technology, which has shown promise for delivering RNAi therapeutics (3/27)

Avecia Inc.*

Various entities

Partnership

Avecia is taking a lead role in a program to establish bioprocessing technology for tissue engineering

Partners in the effort include Durham University, the Blond McIndoe Centre and Smith & Nephew; the UK government is providing funding support (4/24)

BioSystems
International*
(France)

Northeastern University

License agreement

BioSystems licensed rights to a biomarker discovery and development platform

BioSystems gets exclusive, worldwide rights to the monoclonal antibody-based technology; terms were not disclosed (3/10)

Callisto
Pharmaceuticals
Inc.
(AMEX:KAL)

University of Texas M.D. Anderson Cancer Center

Research agreement

M.D. Anderson will support development of the company's Degrasyn class of cancer compounds

Callisto is sponsoring research for two years at the cancer center, which previously licensed the compounds to Callisto (5/10)

Cel-Sci Corp.
(AMEX:CVM)

Naval Medical Research Center of the U.S. Navy

CRADA

They extended a deal to evaluate CEL-SCI's CEL-1000 in malaria applications

They are evaluating the small- peptide agent against several species of malaria and as an adjuvant with various malaria vaccines (4/20)

Ceragenix
Pharmaceuticals
Inc.*

Johns Hopkins University School of Medicine

Research agreement

Hopkins researchers will evaluate an anti- microbial wound dressing from Ceragenix

The Johns Hopkins Burn Center will evaluate the product in animal models of certain infections (5/10)

Chimerix Inc.*

U.S. Army Medical Research Institute of Infectious Diseases

CRADA

Deal to to evaluate Chimerix's smallpox therapeutic, CMX001, in animal models

Chimerix will test CMX001 and potentially other candidates in USAMRIID's animal models of smallpox and monkey pox infection (4/18)

Circadian
Technologies
Ltd.
(Australia;
ASX:CIR)

Ludwig Institute for Cancer Research (Germany) and the University of Helsinki

Venture

The parties formed a company, Vegenics Ltd., to develop and sell vascular endothelial growth factors in cancer indications

Vegenics is 50% owned by Circadian and 50% by LICR and university affiliate Licentia Ltd.; Circadian is providing an initial equity investment in Vegenics (5/1)

Clinical Data
Inc.
(CLDA)

Institute for Genome Sciences & Policy at Duke University

Agreement

IGSP is getting access to studies on genetic variants associated with the effect of statins on lipid parameters

Clinical Data will get the first right to negotiate a commercial license to resulting findings under the five-year deal (5/12)

Cronos
Therapeutics
Ltd.*
(UK)

Cancer Research Technology Ltd. (UK)

Collaboration

To develop a cancer therapy based on Cronos' GeneICE platformtechnology

GeneICE is an epigenetic gene regulation technology; they will work on inhibiting expression of an undisclosed gene target (3/27)

CytoGenix
Inc.
(OTC BB:
CYGX)

University of Texas Medical Branch at Galveston

Research agreement

Deal for preclinical animal studies of the company's synDNA H5N1 vaccine

The synthetic synDNA technology is designed to produce millions of doses of a DNA vaccinewithin a few months (5/16)

DNAPrint
Genomics Inc.
(OTC BB:DNAG)

Massachusetts College of Pharmacy and Health Sciences

Sponsored research agreement

Deal to study analogues of Ritalin for treating various conditions

The goal is to developtest/drug
combinations for drug
abuse, attention deficit
hyperactivitydisorder and depression (3/3)

Dyadic
International
Inc.
(AMEX:DIL)

The Scripps Research Institute

Agreement

Deal to provide a complete annotation of the genome of a fungal organism

Scripps will help annotate the Chrysosporium lucknowense organism from Dyadic; terms were not disclosed (3/31)

Edison
Pharmaceuticals
Inc.*

University of Bologna (Italy) and Columbia University Medical Center

Collaboration

To discover treatments for treating inherited mitochondrial diseases

They plan to identify new classes of compounds targeting diseases of the eye and brain, as well as molecular targets and clinical biomarkers (3/16)

EvoGenix Ltd.
(Australia; ASX:EGX)

University of Massachusetts Medical School

License agreement

Evogenix got rights to an anticancer hamster antibody, DMF10

UMMS is entitled to an upfront payment, as well as potential milestone payments and a small royalty on any resulting sales (4/10)

Evotec AG
(Germany; FSE:EVT)

University of Cincinnati and Cincinnati Children's Hospital Medical Center

Purchase agreement

Deal for the purchase of Evotec's ultra-high-throughput screening system

The $2.8M system will be housed at UC's Genome Research Institute and eventually will be used by researchers throughout Ohio (4/4)

4SC AG
(Germany; FSE:VSC)

University of Münster (Germany)

Collaboration

Deal to develop an agent for treating influenza virus infections

4SC will work with the university's Institute of Molecular Virology in the effort; terms were not disclosed (4/12)

Gen-Probe
Inc.
(GPRO)

University of Michigan

License agreement

Gen-Probe got rights to develop diagnostic tests based on genetic translocations

UM gets $0.5M up front, research funding, and potential milestone and royalty payments; the technology has been shown to be highly specific for prostate cancer tissue (5/1)

Geron Corp.
(GERN)

University of Oxford (UK)

License and research agreements

Geron licensed rights to technology on dendritic cells derived from human embryonic stem cells

Geron also will fund work at the university to further develop the technology (3/27)

HaptoGuard
Inc.*

University of Calgary (Canada)

License agreement

HaptoGuard got world- wide rights to a family of compounds directed against cardiovascular disease

The compounds are glutathione peroxidase mimetics; terms of the exclusive deal were not disclosed (5/9)

Illumina Inc.
(ILMN)

Cancer Research UK

Services agreement

Illumina will provide genotyping services on prostate cancer patients and controls

The deal is valued at nearly $7M; under a previous deal, Illumina is providing genotyping in the area of colorectal cancer for Cancer Research UK (4/11)

ImmPORT
Therapeutics
Inc.*

Foundation for Innovative New Diagnostics (Switzerland) and the Public Health Research Institute

Collaboration

Deal to to identify antigens useful for the diagnosis of tuberculosis

ImmPORT's whole-proteome microarray chip technology platform will be used in the effort to develop a fast and affordable diagnostic (5/15)

Incitive Ltd.
(Australia;
ASX:ICV)

Queensland Institute of Medical Research (Australia)

Agreement

Deal to evaluate Incitive's CCS product for inflammation and autoimmune diseases

The deal covers validation and preclinical evaluation of the agent against various disorders; terms were not disclosed (4/20)

Invitrogen
Corp.
(IVGN)

NIH Chemical Genomics Center

Collaboration

Deal to identify small molecules that modulate signaling pathways associated with disease pathophysiology

The NCGC will use Invitrogen's cell lines and beta-lactamase reporter gene technology in the effort; data will be deposited in the NIH's PubChem database (3/6)

Miraculins Inc.
(Canada; CDNX:
MOM)

Duke University

Medical Center

Agreement

Deal to further develop

Miraculins' prostate

cancer diagnostic

project

Duke is providing research capa-

bilities and its patient network to

the effort; terms were not dis-

closed (4/10)

Mymetics Corp. (Switzerland; PK:MYMX)

National Institutes of Health

Agreement

The NIH agreed to test the company's HIV-AIDS mucosal prophylactic vaccine candidate

The preclinical study will test the vaccine in a nonhuman primate model, in parallel to an ongoing preclinical trial (3/9)

NephroGenex
Inc.*

Vanderbilt University

License agreement

NephroGenex got rights covering the use of Pyridorin as a treatment for acute renal failure

Terms of the deal were not dis- closed (5/10)

Norwood
Abbey Ltd.
(Australia; ASX:NAL)

Australian Stem Cell Centre and Monash University (Australia)

Research agreement

To develop a technology platform combining immune system research with stem cell know-how

The focus is on controlling the immune system to minimize rejection of stem cell therapies; Norwood and the ASCC would jointly commercialize resulting technology (3/21)

Open
Biosystems
Inc.*

CIC bioGUNE (Spain)

Agreement

CIC joined OBI's Open Access RNAi Program

Through the deal CIC purchased OBI's whole- enome human retroviral shRNAmir library (5/11)

Open
Biosystems
Inc.*

Northwestern University

Agreement

Northwestern joined OBI's Open Access RNAi Program

The program at Northwestern includes shRNAmir lentiviral libraries targeting the human and mouse genomes (3/8)

Paratek
Pharmaceuticals
Inc.*

Families of Spinal Muscular Atrophy

Collaboration

Deal to develop a small- molecule candidate for treating spinal muscular atrophy

They will focus on optimizing and advancing into the clinic a Paratek compound from the tetracycline class (5/17)

Pharminox
Ltd.*
(UK)

Cancer Research Technology Ltd. (UK)

License agreement

Pharminox got rights to an oncology program focused on targeting telomere signaling

Pharminox has a 12-month option to license exclusive, worldwide rights; terms were not disclosed (4/19)

Phoenix
Biotechnology
Inc.*

Christus Stehlin Foundation

Collaboration

Deal to investigate a Phoenix drug against melanoma

Phoenix is developing botanical extracts in collaboration with the University of Texas M.D. Anderson Cancer Center (5/3)

PhytoMedical
Technologies Inc.
(Canada; OTC BB:
PYTO)

Iowa State University and the USDA's Agricultural Research Service

Extended CRADA

New deal designed to accelerate plans to develop a compound for treating Type II diabetes

The research is focused on synthesizing certain insulin-enhancing or mimetic polyphenolic compounds designed to improve insulin function (3/21)

Primagen
Holding BV*
(the Netherlands)

University of Texas M.D. Anderson Cancer Center

License agreement

Primagen expanded its rights to the CD133 diagnostic biomarker

Its worldwide license to the bio- marker was expanded to include the cardiovascular field; terms were not disclosed (4/25)

Primagen
Holding BV*
(the Netherlands)

European Union

Agreement

Primagen was chosen to participate in the EU- funded GRACE project on combating antibiotic resistance

Primagen will screen samples of patients with respiratory tract infections to identify novel viruses, along with the Leiden University Medical Center (3/28)

Reata
Pharmaceuticals
Inc.*

Dartmouth College and the M.D. Anderson Cancer Center

License agreement

Reata got exclusive rights to a new class of anti- inflammatory compounds

The compounds, tricyclic bisenones, are activators of the transcription factor Nrf2; terms were not disclosed (4/17)

Santaris
Pharma A/S*
(Denmark)

University of Copenhagen (Denmark)

Agreement

They formed a microRNA research consortium

The work focused on developing microRNAs as drug targets is being funded in part by the Danish Advanced Technology Foundation (5/1)

Serologicals
Corp.
(SERO)

Australian Stem Cell Centre

Agreement

A Serologicals subsidiary got rights to stem cell reagents developed at ASCC

Chemicon International Inc. got exclusive rights to commercialize and distribute the reagents to scientists worldwide (4/21)

Shanghai
Wanxing Bio-
Pharmaceuticals
Co.*
(China)

PATH Malaria Vaccine Initiative

Agreement

PATH will support development of a pediatric malaria vaccine against Plasmodium falciparum

The deal will allow for improvements in the manufacturing process and lead to a safety evaluation of the vaccine candidate, PfCP2.9 (3/15)

Sirna
Therapeutics
Inc.
(RNAI)

University of Massachusetts Medical School

License agreement

Sirna got rights to patents covering microRNA technology for the modulation of gene expression

Sirna got exclusive rights to the Zamore miRNA patents for all uses; terms of the deal were not disclosed (5/10)

SpeciGen Inc.*

Montanta State University

License agreement

SpeciGen got rights to protein cage-based nanotechnologies

The technology will be used for targeted delivery of diagnostic and therapeutic agents; SpeciGen also will sponsor research at MSU (4/28)

Sunesis
Pharmaceuticals
Inc.
(SNSS)

University of California at San Francisco

Research and license agreement

UCSF got rights to use Sunesis' fragment- based Tethering drug discovery technology

Sunesis gets exclusive rights to any resulting improvements to the technology or fragment libraries, and would have first rights to license resulting small-molecule drug candidates (4/7)

Syntarga BV*
(the Netherlands)

Georg-August University (Germany)

License agreement

Syntarga got exclusive, worldwide rights to anticancer agents

Syntarga will incorporate the alkylating agents in antibody- drug and other conjugates; terms were not disclosed (3/14)

Target
Discovery Inc.*

University of Texas M.D. Anderson Cancer Center

Collaboration

To develop a new generation of cancer diagnostic assays

Target Discovery will use its mass defect technology to validate protein biomarkers from samples provided by M.D. Anderson (4/20)

Target
Discovery Inc.*

Eastern Virginia Medical School

Collaboration

To develop clinical assays that will help guide treatment of prostate cancer

They plan to validate protein iso- form biomarkers and integrate them into Target Discovery's Isonostics clinical platform (3/21)

TiGenix Inc.
(unit of TiGenix
NV*; Belgium)

Hospital for Special Surgery

Collaboration

The hospital will help develop TiGenix's lead cartilage repair product

The product, ChondroCelect, is a cell-based therapy designed for the repair of cartilage defects of the knee (3/28)

Vaxon Biotech*
(France)

Institut Pasteur(France)

License deal and collaboration

Deal to develop new vaccine products and animal transgenic models

Vaxon intends to develop products covering major HLA super-families for treating cancers; terms were not disclosed (4/3)

Vertex
Pharmaceuticals
Inc.
(VRTX)

Cystic Fibrosis Foundation Therapeutics Inc.

Collaboration

Deal to to accelerate development of VX-770, an oral agent being developed to treat CF

CFFT will pay Vertex about $13.3M in development support through 2007; Vertex retains worldwide rights (3/23)

VM Discovery
Inc.*

Fred Hutchinson Cancer Research Center

Collaboration

To jointly pursue a discovery program for cancer drugs

VMD will use its design and optimization technology to generate lead compounds, while the center will contribute its expertise; terms were not disclosed (3/31)


Notes:

This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted.

CRADA = Cooperative Research and Development Agreement.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadaian Venture Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets.

No Comments